Faculty Bibliography
Searched for:
person:karajm01
Total Results:
183
Novel Candidate Oncogenic Drivers in Pineoblastoma [Meeting Abstract]
ISI:000354824800135
ISSN: 0022-3069
CID: 1620172
Genomic and Epigenetic Landscape of Sudden Unexpected Death in Epilepsy [Meeting Abstract]
ISI:000354824800017
ISSN: 0022-3069
CID: 1620452
Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups
Ependymal tumors across age groups are currently classified and graded solely by histopathology. It is, however, commonly accepted that this classification scheme has limited clinical utility based on its lack of reproducibility in predicting patients' outcome. We aimed at establishing a uniform molecular classification using DNA methylation profiling. Nine molecular subgroups were identified in a large cohort of 500 tumors, 3 in each anatomical compartment of the CNS, spine, posterior fossa, supratentorial. Two supratentorial subgroups are characterized by prototypic fusion genes involving RELA and YAP1, respectively. Regarding clinical associations, the molecular classification proposed herein outperforms the current histopathological classification and thus might serve as a basis for the next World Health Organization classification of CNS tumors.
PMCID:4712639
PMID: 25965575
ISSN: 1878-3686
CID: 1578762
Neurofibromatosis-related tumors: emerging biology and therapies
PURPOSE OF REVIEW: Over the past decade, substantial insight into the biological function of the tumor suppressors neurofibromin (NF1) and Merlin (NF2) has been gained. The purpose of this review is to highlight some of the major advances in our understanding of the biology of neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2) as they relate to the development of novel therapies for these disorders. RECENT FINDINGS: The development of increasingly sophisticated preclinical models over the recent years has provided the platform from which to rationally develop molecular targeted therapies for both NF1 and NF2-related tumors, such as within the Department of Defense-sponsored Neurofibromatosis Clinical Trials Consortium. SUMMARY: Clinical trials with molecular-targeted therapies have become a reality for neurofibromatosis patients, and hold substantial promise for improving the morbidity and mortality of individuals affected with these disorders.
PMCID:4374132
PMID: 25490687
ISSN: 1040-8703
CID: 1459772
Schwannomas
NEW YORK : SPRINGER, 2015
pp. 201-211
ISBN:
CID: 2658812
Hereditary Predisposition to Primary CNS Tumors
NEW YORK : SPRINGER, 2015
pp. 1-22
ISBN:
CID: 2658802
Novel candidate oncogenic drivers in pineoblastoma [Meeting Abstract]
ISI:000371597100272
ISSN: 1538-7445
CID: 2064382
Clinical response to bevacizumab in schwannomatosis
PMCID:4248457
PMID: 25339217
ISSN: 0028-3878
CID: 1368962
Recurrent Ascites in a Patient With Low-grade Astrocytoma and Ventriculo-Peritoneal Shunt Treated With the Multikinase Inhibitor Sorafenib
This report describes a 6-year-old boy with disseminated low-grade astrocytoma and ventriculo-peritoneal shunt, who developed recurrent ascites while receiving sorafenib on a clinical trial. Laboratory analysis of the peritoneal fluid showed no elevation of protein content and no evidence of underlying infection or tumor dissemination. This report highlights ascites as a previously unrecognized adverse reaction to sorafenib in a patient with a ventriculo-peritoneal shunt. We conclude that such patients should be closely monitored for this complication when treated with sorafenib.
PMID: 24351969
ISSN: 1077-4114
CID: 760302
Next-generation neuropathology - Improving diagnostic accuracy for brain tumors using DNA methylation array-based molecular profiling [Meeting Abstract]
ISI:000349906902106
ISSN: 1538-7445
CID: 1599132
